ArticleJournal of the American Heart Association2025
Population-Based Study on the Coexistence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.Hepatology international · 2026Article
- Endothelial Cells at the Crossroad of Atherosclerosis and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Unifying Target for Dual Treatment.JACC. Basic to translational science · 2026Review
- Article
- Myocardial Infarction Without Standard Modifiable Risk Factors From 2025-2040: Forecast Analysis of Multinational, Population-Based Study.JACC. Asia · 2026Article
- Systematic review of cardiovascular care delivery across health systems in the Asia-Pacific: a regional roadmap for strengthening cardiovascular care.The Lancet regional health. Western Pacific · 2026Article
- Inflammatory Adipokines and Potential Oxidative Stress-Related Mechanisms Linking MASLD with Subclinical Atherosclerosis Within CKM Syndrome: A Systematic Review and Meta-Analysis.Antioxidants (Basel, Switzerland) · 2026Review
- Associations of Metabolic Phenotypes with Cardiac Structure and Clinical Outcomes: Insights from the UK Biobank.The Journal of clinical endocrinology and metabolism · 2026Article
- Article
- Long-term prognosis of coexistent metabolic dysfunction-associated steatotic liver disease and chronic kidney disease following acute myocardial infarction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Real-world diagnostic performance of blood-based biomarkers for Alzheimer's disease: robust performance except after stroke and high charlson comorbidity index.Alzheimer's research & therapy · 2026Article
- Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: A population-based study.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) are important cardiovascular risk factors. However, the prognostic impact of coexisting MASLD and CKD remains understudied.
methodsThis study cohort used the NHANES (National Health and Nutrition Examination Survey) 2007 to 2018 database, examining outcomes in adults with varying MASLD and CKD statuses. The primary outcome was all-cause mortality. Secondary outcomes included coronary heart disease, heart failure, stroke, and cancer. Cox regression model was constructed to investigate the relationship between MASLD/CKD and all-cause mortality, adjusted for age, prior coronary heart disease, body mass index, smoking, poverty-to-income ratio, lipid-lowering and glucose-lowering medications. Sensitivity analysis was performed with hepatic fibrosis and CKD.
resultsAmong 14 818 participants (mean follow-up: 6.9 ± 3.4 years), a majority of participants had MASLD(-)/CKD(-) (50.8%), followed by MASLD(+)/CKD(-) (34.8%), MASLD(+)/CKD(+) (7.7%), and MASLD(-)/CKD(+) (6.7%). MASLD(+)/CKD(+) (n = 1142) had the highest rates of obesity (77.6%), hypertension (77.5%), dyslipidemia (67.0%), and diabetes (49.7%), with the highest risk of coronary heart disease (risk ratio [RR], 1.79 [95% CI, 1.13-2.82],
conclusionsMASLD(+)/CKD(+) phenotype increases the risk of cardiometabolic multimorbidity and independently predicts mortality. Mortality risk increased progressively in individuals with both advanced hepatic fibrosis and CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.